CC Chemours (CC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0001627223
Cluster · 7 insidersC-suite buying · 5
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
218
13F, latest reported quarter
What the filings say about CC
Insiders, 180 days
+$488.6K net bought
7 buyers
Chemours insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Chemours Co insiders bought a net $488.6K of stock across 50 Form 4 purchases and sales, with 7 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.3% of the 58,547 shares held after it.
- 6 other insiders bought within 30 days.
- 218 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Familiar Calderon Gerardo bought about $30.1K of CC on Aug 12, 2026; 6 other insiders bought within 30 days and 218 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Aug 8, 2025.
- The trade is 1.0% of the 339,916 shares held after it.
- 6 other insiders bought within 30 days.
- 218 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dignam Denise bought about $50.5K of CC on Aug 11, 2026; 6 other insiders bought within 30 days and 218 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- 6 other insiders bought within 30 days.
- 218 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Foley Michael Robert bought about $30.0K of CC on Aug 7, 2026; 6 other insiders bought within 30 days and 218 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 22.8% of the 56,988 shares held after it.
- 6 other insiders bought within 30 days.
- 218 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cowan Alister bought about $203.1K of CC on Aug 7, 2026, the largest insider purchase at the company since 2023; 6 other insiders bought within 30 days and 218 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.5% of the 55,431 shares held after it.
- 6 other insiders bought within 30 days.
- 218 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Martinko Joseph T. bought about $30.0K of CC on Aug 7, 2026; 6 other insiders bought within 30 days and 218 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$488.6K over 180 days
+$488.6K over 90 days
more than 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
218 funds bought in last quarter
more than 91% of Pharma & Biotech
Revenue
+0.4% year over year
below 53% of Pharma & Biotech
Margin
-6.6% net margin
more than 67% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.3% of the float short (float per yahoo 2026-10-26) · 8.2 days to cover · settled 2026-09-30
more than 72% of Pharma & Biotech
The situation: each line is one rule over one dataset
7 insiders independently bought a net $488.6K while the stock fell 52% over six months, with no planned sales queued.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-3.2%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CC: institutional holders (13F)
13F holdings, latest reported quarter
23,283,074 sh
$477.8M
10,568,867 sh
$216.9M
6,784,588 sh
$139.2M
6,115,375 sh
$125.5M
4,924,004 sh
$101.0M
Congress trades in CC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P SmallCap Materials ETF
$916.6K position · as of 2026-05-31
4.4%
ICON EQUITY INCOME FUND
$1.8M position · as of 2026-06-30
4.0%
ICON EQUITY FUND
$1.4M position · as of 2026-06-30
2.3%
ICON Natural Resources and Infrastructure Fund
$3.0M position · as of 2026-06-30
2.2%
Columbia Select Small Cap Value Fund
$7.4M position · as of 2026-05-31
1.8%
JPMorgan U.S. Large Cap Value Plus ETF
$424.7K position · as of 2026-07-31
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Newman
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$7.3M
n/a
$1.5M
+104%
+50%
2021
$5.5M
n/a
$2.4M
+104%
+52%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
7 insiders reported buying shares.
The record shows a net $488.6K bought by insiders over 180 days, 218 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CC financials
Revenue growth
+0.4%
XBRL, annual
Net margin
-6.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.8B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CC
| FY Dec 2025 | $5.8B |
| FY Dec 2024 | $5.8B |
| FY Dec 2023 | $6.1B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $6.3B |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.5B |
| Jun 2025 | $1.6B |
| Mar 2025 | $1.4B |
| Dec 2024 | $1.4B |
| Sep 2024 | $1.5B |
At each fiscal year end
Single quarter
Net margin, TTM
-5.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CC
| FY Dec 2025 | -6.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +9.6% |
| Jun 2026 | -17.2% |
| Mar 2026 | -2.1% |
| Dec 2025 | -3.5% |
| Sep 2025 | +3.1% |
| Jun 2025 | -23.5% |
| Mar 2025 | -0.4% |
| Dec 2024 | -0.8% |
| Sep 2024 | -2.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$218.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CC
| FY Dec 2025 | $51.0M |
| FY Dec 2024 | -$993.0M |
| FY Dec 2023 | $186.0M |
| FY Dec 2022 | $448.0M |
| FY Dec 2021 | $537.0M |
| Jun 2026 | $114.0M |
| Mar 2026 | -$93.0M |
| Dec 2025 | $92.0M |
| Sep 2025 | $105.0M |
| Jun 2025 | $50.0M |
| Mar 2025 | -$196.0M |
| Dec 2024 | $29.0M |
| Sep 2024 | $63.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CC
| FY Dec 2025 | 16.56x |
| FY Dec 2024 | 7.20x |
| FY Dec 2023 | 5.60x |
| FY Dec 2022 | 3.28x |
| FY Dec 2021 | 3.47x |
| Jun 2026 | n/a |
| Mar 2026 | 19.24x |
| Dec 2025 | 16.56x |
| Sep 2025 | 15.17x |
| Jun 2025 | 18.18x |
| Mar 2025 | 7.27x |
| Dec 2024 | 7.20x |
| Sep 2024 | 6.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.10x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CC
| FY Dec 2025 | 0.06x |
| FY Dec 2024 | -0.15x |
| FY Dec 2023 | 0.14x |
| FY Dec 2022 | 0.21x |
| FY Dec 2021 | 0.22x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.08x |
| Dec 2025 | 0.06x |
| Sep 2025 | 0.06x |
| Jun 2025 | 0.06x |
| Mar 2025 | -0.11x |
| Dec 2024 | -0.15x |
| Sep 2024 | -0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-339.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CC
| FY Dec 2025 | -94.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +52.8% |
| FY Dec 2021 | +64.3% |
| Jun 2026 | -339.7% |
| Mar 2026 | -105.0% |
| Dec 2025 | -94.0% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CC
| FY Dec 2025 | -5.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +7.6% |
| FY Dec 2021 | +8.3% |
| Jun 2026 | -4.2% |
| Mar 2026 | -5.6% |
| Dec 2025 | -5.2% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital CC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed CC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CC
| FY Dec 2025 | n/a |
| FY Dec 2024 | 37.56x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 8.60x |
| FY Dec 2021 | 9.27x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 225.50x |
| Dec 2024 | 37.56x |
| Sep 2024 | 49.56x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.1B
market value at close 2026-10-23 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CC
| FY Dec 2025 | $5.2B |
| FY Dec 2024 | $5.9B |
| FY Dec 2023 | $7.5B |
| FY Dec 2022 | $7.2B |
| FY Dec 2021 | $7.8B |
| Jun 2026 | $6.3B |
| Mar 2026 | $6.9B |
| Dec 2025 | $5.2B |
| Sep 2025 | $5.9B |
| Jun 2025 | $5.4B |
| Mar 2025 | $5.7B |
| Dec 2024 | $5.9B |
| Sep 2024 | $6.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+11.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield CC
| FY Dec 2025 | +2.9% |
| FY Dec 2024 | -39.3% |
| FY Dec 2023 | +4.0% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | +9.8% |
| Jun 2026 | +7.1% |
| Mar 2026 | +4.7% |
| Dec 2025 | +2.9% |
| Sep 2025 | -0.5% |
| Jun 2025 | -3.2% |
| Mar 2025 | -39.4% |
| Dec 2024 | -39.3% |
| Sep 2024 | -22.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.05x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2025-09 | 2025-06 | 2025-03 | |
|---|---|---|---|---|
| Revenue | $5.8B | n/a | n/a | n/a |
| Gross profit | $902.0M | n/a | n/a | n/a |
| Net income | -$386.0M | n/a | n/a | n/a |
| EPS (diluted) | -2.57 | n/a | n/a | n/a |
| Operating cash flow | $264.0M | n/a | n/a | n/a |
| Cash | $670.0M | n/a | n/a | n/a |
| Long-term debt | $4.1B | $4.1B | $4.1B | $4.1B |
| Dividends paid | $78.0M | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
CC Stock Sonar score 6/7 axes
Find similar shapesCompareCC ranks highest on insider conviction (92nd percentile) and institutional and government (88th), and lowest on risk and compliance (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CC filings, in plain words
Are Chemours insiders buying or selling CC?
In the 180 days to 2026-10-27, Chemours insiders were net buyers, a net $488.6K across purchases and sales reported on Form 4, by 7 buyers.
Read the full summary
In the 180 days to 2026-10-27, Chemours insiders were net buyers of CC, a net $488.6K across purchases and sales reported on Form 4 by 7 buyers. 7 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
